[1] |
Winthrop KL, Marras TK, Adjemian J, et al. Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008—2015. Ann Am Thorac Soc, 2020, 17(2):178-185. doi:10.1513/AnnalsATS.201804-236OC.
doi: 10.1513/AnnalsATS.201804-236OC
pmid: 31830805
|
[2] |
Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med, 2010, 182(7):970-976. doi:10.1164/rccm.201002-0310OC.
doi: 10.1164/rccm.201002-0310OC
URL
|
[3] |
Suresh P, Kumar A, Biswas R, et al. Epidemiology of Nontuberculous Mycobacterial Infection in Tuberculosis Suspects. Am J Trop Med Hyg, 2021, 105(5):1335-1338. doi:10.4269/ajtmh.21-0095.
doi: 10.4269/ajtmh.21-0095
URL
|
[4] |
Kumar K, Loebinger MR. Nontuberculous Mycobacterial Pulmonary Disease: Clinical Epidemiologic Features, Risk Factors, and Diagnosis: The Nontuberculous Mycobacterial Series. Chest, 2022, 161(3):637-646. doi:10.1016/j.chest.2021.10.003.
doi: 10.1016/j.chest.2021.10.003
URL
|
[5] |
Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med, 2011, 183(3):405-410. doi:10.1164/rccm.201003-0395OC.
doi: 10.1164/rccm.201003-0395OC
URL
|
[6] |
Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother, 2009, 53(4):1367-1376. doi:10.1128/AAC.01275-08.
doi: 10.1128/AAC.01275-08
URL
|
[7] |
Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother, 2011, 55(2):775-781. doi:10.1128/aac.00861-10.
doi: 10.1128/aac.00861-10
URL
|
[8] |
Kwak N, Dalcolmo MP, Daley CL, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J, 2019, 54(1):1801991. doi:10.1183/13993003.01991-2018.
doi: 10.1183/13993003.01991-2018
|
[9] |
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007, 175(4):367-416. doi:10.1164/rccm.200604-571ST.
doi: 10.1164/rccm.200604-571ST
URL
|
[10] |
Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax, 2016, 71(Suppl 1):i1-i22. doi:10.1136/thoraxjnl-2015-207360.
doi: 10.1136/thoraxjnl-2015-207360
URL
|
[11] |
中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11):918-946. doi:10.3760/cma.j.cn112147-20200508-00570.
doi: 10.3760/cma.j.cn112147-20200508-00570
|
[12] |
Bao JR, Clark RB, Master RN, et al. Acid-fast bacterium detection and identification from paraffin-embedded tissues using a PCR-pyrosequencing method. J Clin Pathol, 2018, 71(2):148-153. doi:10.1136/jclinpath-2016-204128.
doi: 10.1136/jclinpath-2016-204128
pmid: 28735303
|
[13] |
Ringuet H, Akoua-Koffi C, Honore S, et al. Hsp65 sequencing for identification of rapidly growing mycobacteria. J Clin Microbiol, 1999, 37(3):852-857. doi:10.1128/jcm.37.3.852-857.1999.
doi: 10.1128/jcm.37.3.852-857.1999
pmid: 9986875
|
[14] |
Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017, 72(Suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927.
doi: 10.1136/thoraxjnl-2017-210927
|
[15] |
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020, 56(1):2000535. doi:10.1183/13993003.00535-2020.
doi: 10.1183/13993003.00535-2020
|